Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…
Certara2025 年 6 月 8 日
FDA plans to phase out animal testing requirements
Discover how the FDA plans to replace animal testing with AI and organ-on-chip technologies for…
Certara2025 年 4 月 10 日
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
Certara2025 年 3 月 27 日
JTNDc2NyaXB0JTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZmYXN0Lndpc3RpYS5jb20lMkZwbGF5ZXIuanMlMjIlMjBhc3luYyUzRSUzQyUyRnNjcmlwdCUzRSUzQ3NjcmlwdCUyMHNyYyUzRCUyMmh0dHBzJTNBJTJGJTJGZmFzdC53aXN0aWEuY29tJTJGZW1iZWQlMkZsdXRzdGhodmZvLmpzJTIyJTIwYXN5bmMlMjB0eXBlJTNEJTIybW9kdWxlJTIyJTNFJTNDJTJGc2NyaXB0JTNFJTNDc3R5bGUlM0V3aXN0aWEtcGxheWVyJTVCbWVkaWEtaWQlM0QlMjdsdXRzdGhodmZvJTI3JTVEJTNBbm90JTI4JTNBZGVmaW5lZCUyOSUyMCU3QiUyMGJhY2tncm91bmQlM0ElMjBjZW50ZXIlMjAlMkYlMjBjb250YWluJTIwbm8tcmVwZWF0JTIwdXJsJTI4JTI3aHR0cHMlM0ElMkYlMkZmYXN0Lndpc3RpYS5jb20lMkZlbWJlZCUyRm1lZGlhcyUyRmx1dHN0aGh2Zm8lMkZzd2F0Y2glMjclMjklM0IlMjBkaXNwbGF5JTNBJTIwYmxvY2slM0IlMjBmaWx0ZXIlM0ElMjBibHVyJTI4NXB4JTI5JTNCJTIwcGFkZGluZy10b3AlM0ExMDAuMCUyNSUzQiUyMCU3RCUzQyUyRnN0eWxlJTNFJTIwJTNDd2lzdGlhLXBsYXllciUyMG1lZGlhLWlkJTNEJTIybHV0c3RoaHZmbyUyMiUyMGFzcGVjdCUzRCUyMjEuMCUyMiUzRSUzQyUyRndpc3RpYS1wbGF5ZXIlM0U=
Certara2025 年 3 月 26 日
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
Certara2025 年 3 月 26 日
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
Certara2025 年 3 月 24 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…
Certara2025 年 3 月 20 日
How biosimulation and virtual trials can bust through clinical trial roadblocks
Discover how using biosimulation for rare disease drug development can help overcome statistical and recruitment…
Certara2025 年 3 月 14 日
MIDD in Japan – Implementations, challenges and opportunities
In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…
Certara2025 年 3 月 12 日
